0
0
Home > Pharmaceuticals >  Immunology >  Systemic Sclerosis (Scleroderma) – Epidemiology Forecast to 2030

Systemic Sclerosis (Scleroderma) – Epidemiology Forecast to 2030

Systemic sclerosis (SSc) is an autoimmune disorder of small arteries, microvessels, and connective tissue. SSc is characterized by the buildup of scar tissue (fibrosis) and vascular obliteration in the skin and organs, particularly the lungs, heart, and digestive tract (Orphanet, 2010). The signs and symptoms of SSc usually begin with episodes of Raynaud's phenomenon (RP). The other signs usually appear a few months later in the dcSSc subset and some years later in the lcSSc subset. In lcSSc, skin involvement is limited to the hands, face, feet and forearms while in the dcSSc it rapidly becomes generalized. The most commonly affected organs are the esophagus, heart, lungs, and kidneys (Genetic and Rare Diseases Information Center, 2018).

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for SSc in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of SSc. The diagnosed prevalent cases of SSc are segmented by age (18 years and older), sex, subtype (lcSSc and dcSSc), digital vasculopathy (RP and fingertip or DUs), and other internal organ involvement (ILD, PAH, kidney disease, cardiac involvement, gastrointestinal involvement, musculoskeletal involvement, and neuromuscular involvement). The report also includes SSc cases with comorbid malignancy. The following data describes epidemiology of SSc. In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of SSc from 170,921 cases in 2020 to 187,518 cases in 2030, at an AGR of 0.97% over the forecast period. Women accounted for more diagnosed prevalent cases of SSc than men in the 7MM and it predominantly affects older adults. These findings are in line with the GlobalData estimates and these trends are reflected in GlobalData’s forecast for the diagnosed prevalent cases for the 7MM.

Scope

The Systemic Sclerosis (SSc) Epidemiology Report and Model provide an overview of the risk factors and global trends of SSc in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of SSc segmented by sex and age (ages ≥18 years). The diagnosed prevalent cases of SSc are further segmented by subtype (lcSSc and dcSSc), digital vasculopathy (Raynaud’s phenomenon [RP] and fingertip or digital ulcers [DU]), and other internal organ involvement (interstitial lung disease [ILD], pulmonary arterial hypertension [PAH], kidney disease, cardiac involvement, gastrointestinal involvement, musculoskeletal involvement, and neuromuscular involvement). The report also includes SSc cases with comorbid malignancy. The model associated with this report additionally provides diagnosed incident cases and total prevalent cases of SSc segmented by age (≥18 years) and sex.

The SSc epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Systemic Sclerosis Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global SSc market.

Quantify patient populations in the global SSc market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SSc therapeutics in each of the markets covered.

Understand magnitude of SSc population by subtype, digital vasculopathy, and other internal organ involvement.

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Systemic Sclerosis: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 7MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc – 7MM

2.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of SSc by Subtype

2.4.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy

2.4.6 Diagnosed Prevalent Cases of by other Internal Organ Involvement and Comorbidities

2.5 Epidemiological Forecast for Systemic Sclerosis (Scleroderma) (2020–2030)

2.5.1 Diagnosed Prevalent Cases of SSc

2.5.2 Age-Specific Diagnosed Prevalent Cases of SSc

2.5.3 Sex-Specific Diagnosed Prevalent Cases of SSc

2.5.4 Diagnosed Prevalent Cases of SSc by Subtype

2.5.5 Diagnosed Prevalent Cases of SSc by Digital Vasculopathy

2.5.6 Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement

2.5.7 Diagnosed Prevalent Cases of SSc with Comorbid Malignancy

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

3.3 Contact Us

List of Tables

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbidities for SSc

Table 4: Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement

List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of SSc, Both Sexes, N, Ages ≥18 Years, 2020 and 2030

Figure 2: 7MM, Diagnosed Prevalence of SSc, Men and Women, %, Ages ≥18 Years, 2020

Figure 3: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of SSc

Figure 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Subtype

Figure 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Digital Vasculopathy

Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement – ILD, PAH, and Kidney Disease

Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SSc by Other Internal Organ Involvement – Cardiac Involvement, Gastrointestinal Involvement, Musculoskeletal Involvement, and Neuromuscular Involvement; and Comorbidity – Malignancy

Figure 8: 7MM, Diagnosed Prevalent Cases of SSc, N, Both Sexes, Ages ≥18 Years, 2020

Figure 9: 7MM, Diagnosed Prevalent Cases of SSc by Age, N, Both Sexes, 2020

Figure 10: 7MM, Diagnosed Prevalent Cases of SSc by Sex, N, Ages ≥18 Years, 2020

Figure 11: 7MM, Diagnosed Prevalent Cases of SSc by Subtype, N, Both Sexes, Ages ≥18 Years, 2020

Figure 12: 7MM, Diagnosed Prevalent Cases of SSc by Digital Vasculopathy, N, Both Sexes, Ages ≥18 Years, 2020

Figure 13: 7MM, Diagnosed Prevalent Cases of SSc with Comorbid Malignancy, N, Both Sexes, Ages ≥18 Years, 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports